Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. ClouDr Group's annualized net income for the quarter that ended in Dec. 2025 was €-90.9 Mil. ClouDr Group's average Total Stockholders Equity over the quarter that ended in Dec. 2025 was €91.4 Mil. Therefore, ClouDr Group's annualized ROE % for the quarter that ended in Dec. 2025 was -99.55%.
The historical rank and industry rank for ClouDr Group's ROE % or its related term are showing as below:
FRA:H3L'
s ROE % Range Over the Past 10 Years
Min: -94.81 Med: -31.07 Max: -17.4
Current: -94.81
During the past 7 years, ClouDr Group's highest ROE % was -17.40%. The lowest was -94.81%. And the median was -31.07%.
FRA:H3L's ROE % is ranked worse than 95.65% of 115
companies
in the Medical Distribution industry
Industry Median: 7.25
vs FRA:H3L: -94.81
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is two times the semi-annual (Dec. 2025) net income data. The Revenue data used here is two times the semi-annual (Dec. 2025) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
ClouDr Group ROE % Related Terms
ClouDr Group ROE % Historical Data
* Premium members only.
The historical data trend for ClouDr Group's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, ClouDr Group's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ClouDr Group ROE % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, ClouDr Group's ROE % distribution charts can be found below:
* The bar in red indicates where ClouDr Group's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
ROE % is displayed in the 30-year financial page.
ClouDr Group (FRA:H3L) has a ROE % of -99.55% as of Dec. 2025. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on ClouDr Group and its competitors. According to the industry distribution chart, ClouDr Group ranks #110 out of 115 companies in the Medical Distribution industry, placing it in the top 95.7%.
Is ClouDr Group's ROE % too high?
ClouDr Group's current ROE % is -99.55%. Based on the distribution chart, ClouDr Group ranks #110 out of 115 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, ClouDr Group has a GF Score™ of 48/100, reflecting its overall financial health beyond just this single metric.
How does ClouDr Group's ROE % compare to MCK and COR?
According to the Medical Distribution industry distribution chart, ClouDr Group ranks #110 out of 115 companies for ROE %. This places ClouDr Group in the lower half of its industry. The industry median ROE % is 7.25. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Medical Distribution company?
The median ROE % among Medical Distribution companies is 7.25, based on 115 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on ClouDr Group and its competitors. For the Medical Distribution industry, the median ROE % is 7.25 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ClouDr Group's current ROE % is -99.55%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ClouDr Group stock overvalued right now?
ClouDr Group (FRA:H3L) has a current ROE % of -99.55%. The stock's GF Value™ is €0.08, compared to a current price of €0.05 — trading 36.9% below its estimated fair value. The current ROE % is -99.55%. ClouDr Group's overall GF Score™ is 48/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For ClouDr Group (FRA:H3L), the current ROE % is -99.55% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ClouDr Group (FRA:H3L) Overvalued in 2026?
Based on GuruFocus' analysis, ClouDr Group stock appears to be undervalued.
The current stock price of €0.05 is trading 36.9% below its estimated GF Value™ of €0.08.
Key valuation signals for FRA:H3L:
ROE %: -99.55%
GF Value™: €0.08 vs. price of €0.05 (36.9% below fair value)
No single metric tells the full story. See the FRA:H3L stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ClouDr Group Ltd provides supplies and SaaS to hospitals and pharmacies, digital marketing services to pharmaceutical companies, and online consultation and prescriptions to patients, all centered around chronic condition management. The company's in-hospital solution consists of sales of medical devices, consumables, and pharmaceuticals, hospital SaaS, and digital marketing services to pharmaceutical companies, and the out-of-hospital solution connects doctors and patients, and provides high-quality and trustworthy medical services through the AI vertical model ClouD GPT. The company generates revenues from sales of hospital and pharmacy supplies and individual chronic condition management products.
48GF Score
Get the complete analysis for FRA:H3L
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:H3L has been successfully added to your 
